Faron Pharmaceuticals
 | You can help expand this article with text translated from the corresponding article in Finnish. (May 2020) Click [show] for important translation instructions.
|
| Company type | Public |
|---|---|
| AIM: FARN | |
| Industry | Biopharmaceutical, Healthcare |
| Founded | 2003 |
| Founder | Markku Jalkanen and others |
| Headquarters | Turku, Finland |
Key people | Markku Jalkanen CEO |
| Products | Traumakine, Clevegen |
| Website | http://www.faron.com/ |
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.[1]
Its lead product Traumakine has been developed to treat Acute Respiratory Distress Syndrome (ARDS). It is currently (2019) undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and Remap-Cap trials to find drugs for the symptoms of Covid_19
Faron’s other products include the anti-Clever-1 antibody Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach. Current encouraging phase I/II clinical trials in Europe are soon to be extended to America.
Faron Pharmaceuticals is listed in London on the London Stock Exchange's Alternative Investment Market (AIM).
References
- ^ "Faron enters into an agreement with Abzena for the manufacture of Clevegen®". Abzena. Retrieved 6 December 2019.